Literature DB >> 11452702

P-glycoprotein interactions of nefazodone and trazodone in cell culture.

E Störmer1, L L von Moltke, M D Perloff, D J Greenblatt.   

Abstract

This study investigated the effects of nefazodone (NFZ) and trazodone (TZD) on P-glycoprotein (P-gp) activity and expression in cell culture. NFZ and TZD showed no differential transport between the basolateral to apical and apical to basolateral direction across Caco-2 cell monolayers. Transport in either direction was not affected by verapamil. NFZ was a potent inhibitor (IC50 = 4.7 microM) of rhodamine123 (Rh123) B to A transport across Caco-2 cell monolayers, while TZD had minimal effect. Following 72-hour exposure of LS180V cells to NFZ and TZD (10 microM), a twofold increase in immunoreactive P-gp was observed. Rh123 accumulation into these cells was reduced to 65% and 74% of control by NFZ and TZD (10 microM), respectively. It was concluded that differential rates of transport of NFZ and TZD in Caco-2 cells were not evident. However, NFZ is an inhibitor of P-gp activity at clinically relevant in vivo concentrations and may have the potential to increase bioavailability of coadministered compounds that are substrates for transport. Concentrations of NFZ and TZD achieved in the intestine after chronic oral dosing may induce P-gp expression and reduce absorption of coadministered drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11452702     DOI: 10.1177/00912700122010609

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.

Authors:  M D Perloff; L L von Moltke; E Störmer; R I Shader; D J Greenblatt
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 3.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein.

Authors:  Jun-Sheng Wang; Hao-Jie Zhu; Bryan Bradford Gibson; John Seth Markowitz; Jennifer Lyn Donovan; Carl Lindsay DeVane
Journal:  Biol Pharm Bull       Date:  2008-02       Impact factor: 2.233

5.  Rapid assessment of P-glycoprotein inhibition and induction in vitro.

Authors:  Michael D Perloff; Elke Störmer; Lisa L von Moltke; David J Greenblatt
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

6.  Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants.

Authors:  Kuo-Hsuan Chang; Chiung-Mei Chen; Chun-Li Wang; Hui-Tzu Tu; Yu-Tung Huang; Hsiu-Chuan Wu; Chien-Hung Chang; Shang-Hung Chang
Journal:  Front Aging Neurosci       Date:  2022-02-04       Impact factor: 5.750

Review 7.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.